- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 16/46 - Hybrid immunoglobulins
Patent holdings for IPC class C07K 16/46
Total number of patents in this class: 7299
10-year publication summary
|
449
|
506
|
584
|
658
|
645
|
616
|
670
|
668
|
514
|
167
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 4211 |
236 |
| F. Hoffmann-La Roche AG | 7912 |
175 |
| Hoffmann-La Roche Inc. | 3357 |
168 |
| Amgen Inc. | 4024 |
133 |
| Chugai Seiyaku Kabushiki Kaisha | 1333 |
133 |
| Genentech, Inc. | 3935 |
110 |
| Xencor, Inc. | 397 |
104 |
| Janssen Biotech, Inc. | 1518 |
81 |
| The Regents of the University of California | 19784 |
70 |
| Kymab Limited | 250 |
69 |
| Amgen Research (Munich) GmbH | 253 |
65 |
| Zymeworks Inc. | 248 |
65 |
| Merus N.V. | 208 |
60 |
| Novartis AG | 10963 |
56 |
| Ablynx N.V. | 391 |
55 |
| Bristol-myers Squibb Company | 4896 |
50 |
| Sanofi | 4006 |
50 |
| Daiichi Sankyo Company, Limited | 1849 |
47 |
| Genmab A/S | 411 |
46 |
| MacroGenics, Inc. | 232 |
45 |
| Other owners | 5481 |